- Home
- PMI vs AARD Comparison
PMI vs AARD Comparison
Compare PMI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMI | AARD |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.7M | 231.9M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PMI | AARD |
|---|---|---|
| Price | $2.47 | $14.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.63 |
| AVG Volume (30 Days) | ★ 2.5M | 219.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $1.90 | $4.88 |
| 52 Week High | $13.68 | $19.58 |
Technical Indicators
Market Signals| Indicator | PMI | AARD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 65.38 |
| Support Level | N/A | $14.27 |
| Resistance Level | N/A | $16.00 |
| Average True Range (ATR) | 0.00 | 1.07 |
| MACD | 0.00 | 0.52 |
| Stochastic Oscillator | 0.00 | 79.91 |
Price Performance
Historical ComparisonAbout PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.